Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

Qing Zhou, Meghan E. Munger, Rachelle G. Veenstra, Brenda J. Weigel, Mitsuomi Hirashima, David H. Munn, William J. Murphy, Miyuki Azuma, Ana C. Anderson, Vijay K. Kuchroo, Bruce R. Blazar

Research output: Contribution to journalArticle

311 Citations (Scopus)

Abstract

Tumor-associated immune suppression can lead to defective T cell-mediated antitumor immunity. Here, we identified a unique phenotype of exhausted T cells in mice with advanced acute myelogenous leukemia (AML). This phenotype is characterized by the coexpression of Tim-3 and PD-1 on CD8+ T cells in the liver, the major first site of AML metastases. PD-1 and Tim-3 coexpression increased during AML progression. PD-1+Tim-3+ CD8+ T cells were deficient in their ability to produce IFN-γ, TNF-α, and IL-2 in response to PD-1 ligand (PDL1) and Tim-3 ligand (galectin-9) expressing AML cells. PD-1 knockout (KO), which were partially resistant to AML challenge, up-regulated Tim-3 during AML progression and such Tim-3+PD-1- KO CD8+ T cells had reduced cytokine production. Galectin-9 KO mice were more resistant to AML, which was associated with reduced T-regulatory cell accumulation and a modest induction of PD-1 and Tim-3 expression on CD8+ T cells. Whereas blocking the PD-1/ PDL1 or Tim-3/galectin-9 pathway alone was insufficient to rescue mice from AML lethality, an additive effect was seen in reducing - albeit not eliminating - both tumor burden and lethality when both pathways were blocked. Therefore, combined PD-1/PDL1 and Tim-3/galectin-9 blockade may be beneficial in preventing CD8+ T-cell exhaustion in patients with hematologic malignancies such as advanced AML.

Original languageEnglish (US)
Pages (from-to)4501-4510
Number of pages10
JournalBlood
Volume117
Issue number17
DOIs
StatePublished - Apr 28 2011

Fingerprint

T-cells
Acute Myeloid Leukemia
T-Lymphocytes
Phenotype
Galectin 3
Galectins
Tumors
Ligands
Liver
Interleukin-2
Hematologic Neoplasms
Regulatory T-Lymphocytes
Tumor Burden
Knockout Mice
Cellular Immunity
Cytokines
Neoplasm Metastasis

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. / Zhou, Qing; Munger, Meghan E.; Veenstra, Rachelle G.; Weigel, Brenda J.; Hirashima, Mitsuomi; Munn, David H.; Murphy, William J.; Azuma, Miyuki; Anderson, Ana C.; Kuchroo, Vijay K.; Blazar, Bruce R.

In: Blood, Vol. 117, No. 17, 28.04.2011, p. 4501-4510.

Research output: Contribution to journalArticle

Zhou, Q, Munger, ME, Veenstra, RG, Weigel, BJ, Hirashima, M, Munn, DH, Murphy, WJ, Azuma, M, Anderson, AC, Kuchroo, VK & Blazar, BR 2011, 'Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia', Blood, vol. 117, no. 17, pp. 4501-4510. https://doi.org/10.1182/blood-2010-10-310425
Zhou, Qing ; Munger, Meghan E. ; Veenstra, Rachelle G. ; Weigel, Brenda J. ; Hirashima, Mitsuomi ; Munn, David H. ; Murphy, William J. ; Azuma, Miyuki ; Anderson, Ana C. ; Kuchroo, Vijay K. ; Blazar, Bruce R. / Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. In: Blood. 2011 ; Vol. 117, No. 17. pp. 4501-4510.
@article{898108aa76744ee69e643f3b8fb9d9e4,
title = "Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia",
abstract = "Tumor-associated immune suppression can lead to defective T cell-mediated antitumor immunity. Here, we identified a unique phenotype of exhausted T cells in mice with advanced acute myelogenous leukemia (AML). This phenotype is characterized by the coexpression of Tim-3 and PD-1 on CD8+ T cells in the liver, the major first site of AML metastases. PD-1 and Tim-3 coexpression increased during AML progression. PD-1+Tim-3+ CD8+ T cells were deficient in their ability to produce IFN-γ, TNF-α, and IL-2 in response to PD-1 ligand (PDL1) and Tim-3 ligand (galectin-9) expressing AML cells. PD-1 knockout (KO), which were partially resistant to AML challenge, up-regulated Tim-3 during AML progression and such Tim-3+PD-1- KO CD8+ T cells had reduced cytokine production. Galectin-9 KO mice were more resistant to AML, which was associated with reduced T-regulatory cell accumulation and a modest induction of PD-1 and Tim-3 expression on CD8+ T cells. Whereas blocking the PD-1/ PDL1 or Tim-3/galectin-9 pathway alone was insufficient to rescue mice from AML lethality, an additive effect was seen in reducing - albeit not eliminating - both tumor burden and lethality when both pathways were blocked. Therefore, combined PD-1/PDL1 and Tim-3/galectin-9 blockade may be beneficial in preventing CD8+ T-cell exhaustion in patients with hematologic malignancies such as advanced AML.",
author = "Qing Zhou and Munger, {Meghan E.} and Veenstra, {Rachelle G.} and Weigel, {Brenda J.} and Mitsuomi Hirashima and Munn, {David H.} and Murphy, {William J.} and Miyuki Azuma and Anderson, {Ana C.} and Kuchroo, {Vijay K.} and Blazar, {Bruce R.}",
year = "2011",
month = "4",
day = "28",
doi = "10.1182/blood-2010-10-310425",
language = "English (US)",
volume = "117",
pages = "4501--4510",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "17",

}

TY - JOUR

T1 - Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

AU - Zhou, Qing

AU - Munger, Meghan E.

AU - Veenstra, Rachelle G.

AU - Weigel, Brenda J.

AU - Hirashima, Mitsuomi

AU - Munn, David H.

AU - Murphy, William J.

AU - Azuma, Miyuki

AU - Anderson, Ana C.

AU - Kuchroo, Vijay K.

AU - Blazar, Bruce R.

PY - 2011/4/28

Y1 - 2011/4/28

N2 - Tumor-associated immune suppression can lead to defective T cell-mediated antitumor immunity. Here, we identified a unique phenotype of exhausted T cells in mice with advanced acute myelogenous leukemia (AML). This phenotype is characterized by the coexpression of Tim-3 and PD-1 on CD8+ T cells in the liver, the major first site of AML metastases. PD-1 and Tim-3 coexpression increased during AML progression. PD-1+Tim-3+ CD8+ T cells were deficient in their ability to produce IFN-γ, TNF-α, and IL-2 in response to PD-1 ligand (PDL1) and Tim-3 ligand (galectin-9) expressing AML cells. PD-1 knockout (KO), which were partially resistant to AML challenge, up-regulated Tim-3 during AML progression and such Tim-3+PD-1- KO CD8+ T cells had reduced cytokine production. Galectin-9 KO mice were more resistant to AML, which was associated with reduced T-regulatory cell accumulation and a modest induction of PD-1 and Tim-3 expression on CD8+ T cells. Whereas blocking the PD-1/ PDL1 or Tim-3/galectin-9 pathway alone was insufficient to rescue mice from AML lethality, an additive effect was seen in reducing - albeit not eliminating - both tumor burden and lethality when both pathways were blocked. Therefore, combined PD-1/PDL1 and Tim-3/galectin-9 blockade may be beneficial in preventing CD8+ T-cell exhaustion in patients with hematologic malignancies such as advanced AML.

AB - Tumor-associated immune suppression can lead to defective T cell-mediated antitumor immunity. Here, we identified a unique phenotype of exhausted T cells in mice with advanced acute myelogenous leukemia (AML). This phenotype is characterized by the coexpression of Tim-3 and PD-1 on CD8+ T cells in the liver, the major first site of AML metastases. PD-1 and Tim-3 coexpression increased during AML progression. PD-1+Tim-3+ CD8+ T cells were deficient in their ability to produce IFN-γ, TNF-α, and IL-2 in response to PD-1 ligand (PDL1) and Tim-3 ligand (galectin-9) expressing AML cells. PD-1 knockout (KO), which were partially resistant to AML challenge, up-regulated Tim-3 during AML progression and such Tim-3+PD-1- KO CD8+ T cells had reduced cytokine production. Galectin-9 KO mice were more resistant to AML, which was associated with reduced T-regulatory cell accumulation and a modest induction of PD-1 and Tim-3 expression on CD8+ T cells. Whereas blocking the PD-1/ PDL1 or Tim-3/galectin-9 pathway alone was insufficient to rescue mice from AML lethality, an additive effect was seen in reducing - albeit not eliminating - both tumor burden and lethality when both pathways were blocked. Therefore, combined PD-1/PDL1 and Tim-3/galectin-9 blockade may be beneficial in preventing CD8+ T-cell exhaustion in patients with hematologic malignancies such as advanced AML.

UR - http://www.scopus.com/inward/record.url?scp=79955977180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955977180&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-10-310425

DO - 10.1182/blood-2010-10-310425

M3 - Article

C2 - 21385853

AN - SCOPUS:79955977180

VL - 117

SP - 4501

EP - 4510

JO - Blood

JF - Blood

SN - 0006-4971

IS - 17

ER -